

Variable	RETINOPATHY POSITIVE					RETINOPATHY NEGATIVE				
	HIV-uninfected (N=751)		HIV infected (N=126)		p	HIV-uninfected (N=369)		HIV-infected (N=59)		p
	N	Value	N	Value		N	Value	N	Value	
Parasite Clearance Time, hours (IQR)	596	42 (30-54)	97	42 (28-54)	0.63	369	36 (24 - 48)	59	42 (24 - 54)	0.37
Fever Clearance Time, hours (IQR)	591	32 (20-54)	90	37 (20-74)	0.069	369	24 (6 - 38)	59	32 (6 - 58)	0.10
Coma Resolution Time, hours (IQR)	563	34 (18-56)	90	42 (22-70)	0.0085	369	18 (10 - 38)	59	16 (6 - 32)	0.32
Fatal-outcome, number (%)	750	140 (18.7%)	126	30 (23.8%)	0.27	367	36 (9.81%)	58	8 (13.8%)	0.86
Survived with sequelae, number (%)	750	64 (8.53%)	126	9 (7.14%)	0.51	367	38 (10.4%)	58	6 (10.3%)	0.56

Supplemental table 1. Disease progression and outcome in retinopathy positive and retinopathy negative children, compared by HIV status.

Sequelae refers to neurological sequelae including focal muscle weakness, visual or hearing defects, gross cognitive deficit or epilepsy.

Supplementary table 2: Comparison between year categories: 1996-2000; 2001-2005; 2006-2011

Year category	1996-2000;			2001-2005			2006-2011		
N ret positive	310			143			424		
CM HIV prevalence	36/310 (11.61%)			34/143 (23.78%)			56/424 (13.21%)		
	HIV neg	HIV pos	P value	HIV neg	HIV pos	P value	HIV neg	HIV pos	P value
Male sex	128/273 46.89%	16/36 (44.4%)	0.860	14/34 (41.18%)	50/108 (46.30%)	0.694	178/368 (48.37%)	36/56 (64.27%)	0.031
Age (months)	32 (21-50)	45.5 (19-43)	0.0039	29 (19-43)	50.5 (34-75)	0.0025	37 (28-54.5)	50.5 (34-75)	0.0012
Fever duration (hours)	48 (36-72)	48 (24-72)	0.7591	48 (24-72)	48 (26-72)	0.8851	48 (48-72)	62.5 (25-72)	0.7100
Coma duration (hours)	5 (3-11)	6 (3-12)	0.8834	6 (3-10)	6 (4-12)	0.6650	8 (4-15)	7 (4-22)	0.8184
Convulsions duration (hours)	4 (2-11)	4 (2-8)	0.8918	6 (3-10)	4.5 (2.5--9.5)	0.4628	8 (4-14)	7.5 (4-15)	0.9346
Temp on admission (°C)	38.6 (37.7-39.4)	38.5 (38-39.7)	0.7970	38.7 (38-39.7)	38.9 (38.2-39.9)	0.4090	38.8 (38-39.5)	38.8 (38.1-40.0)	0.2485
Heart rate on admission (beats/min)	152 (138-168)	152 (138-168)	0.5128	156 (140-168)	160(126-168)	0.6598	155 (140-174)	159 (140-175)	0.6342
Respiratory rate on admission (cycles/min)	44 (36-56)	48 (32- 55)	0.9439	48 (40-59)	36 (48-60)	0.9697	44 (40-54)	48 (41-56)	0.1516
Systolic BP on admission (mmHG)	110 (98-120)	110 (100-120)	0.5712	110 (100-120)	90 (105-120)	0.8878	88 (96- 105)	88 (96-103)	0.7895
Transfusion given Y/N	21/137 (15.33%)	1/24 (4.17%)	0.203	5/64 (7.81%)	3/16 (18.75%)	0.194	179/296 (60.47%)	31/48 (64.48%)	0.635
Neck stiffness	16/265 (6.04%)	3/36 (8.33%)	0.484	4/107 (3.74%)	1/32 (3.03%)	1.000	10/357 (2.72%)	4/56 (7.14%)	0.100
Jaundice noted	N/A	N/A	N/A	N/A	N/A	N/A	26/325 (8%)	4/46 (8.7%)	0.777
Laboratory results									
Admission parasitaemia (per ul)	104168.50 (8427.00-339544.50)	109528 (5042.5-323125)	0.7527	72701.50 (12480-321893)	52560 (18332.50-227715.50)	0.6301	69840 (11880-288000)	72960 (17840-311952)	0.7381
Admission haematocrit (%)	20 (15- 26)	18 (14-25)	0.2165	18 (15-24)	20.50 (15- 24)	0.9564	19 (16-23.20)	18 (13.90-24)	0.3941
Admission blood white cell count (x10⁹/l)	11000 (7400-16800)	10700 (6800-14600)	0.4997	10700 (7,500-15,100)	10100 (6600-17300)	0.9133	9600 (6800-14100)	11100 (8100-18800)	0.1231
Platelet count (x10⁹/l)	60000 (38000-87000)	68000 (45000-89000)	0.5140	64000 (38000-108000)	93000 (57000-141000)	0.1082	54000 (32000-86000)	56000 (31000-95000)	0.4443
Admission lactate (mmol/l)	N/A	N/A	N/A	8.75 (4.70-13.60)	7.10 (4.40-14.20)	0.9076	6.40 (3.30-10.90)	8.55 (3.60-12.65)	0.1592
Admission glucose (mmol/l)	5.40 (4-6.90)	5.10 (3.80-6.10)	0.4161	5.60 (4.50-7.80)	6.80 (5.30-9.00)	0.0560	6 (4.45-7.60)	6.20 (4.65-7.60)	0.8081
Disease progression and outcome data									
Length of stay (days)	3 (2-4)	3 (2-4)	0.6260	3 (2-4)	4 (3-6)	0.0059	3 (3-4)	3.50 (1.50-5)	0.6039
Parasite clearance time (hours)	42 (30-53)	36 (21-51)	0.2158	36 (24-48)	45 (30-54)	0.2192	42 (30-54)	48 (30-54)	0.2499
Fever clearance time (hours)	32 (18-48)	24 (12-48)	0.5720	28 (16-38)	31 (26-87)	0.0243	36 (20-58)	42 (20-78)	0.0750
Coma resolution time (hours)	28 (15.5-54)	35.5 (22-60)	0.1082	30 (15-47)	45 (32-70)	0.0202	38 (20-58)	45 (21-72)	0.2592
Mortality	49/274 (17.88%)	8/36 (22.22%)	0.499	30/109 (27.52%)	7/34 (20.59%)	0.505	61/367 (16.62%)	14/56 (25%)	0.134
Neurological sequelae	26/274 (9.49%)	1/36 (2.78%)	0.383	10/109 (9.17%)	4/34 (11.76%)	0.658	28/367 (7.63%)	4/56 (7.14%)	0.308

Supplemental table 3: Univariate logistic analysis for lactate, gender, age and HIV status

Variable	OR	95% Confidence interval	p-value
Age	0.998	0.991 - 1.005	0.52
Sex/Gender	1.114	0.0794 - 1.562	0.53
Admission lactate	1.117	1.064 - 1.174	<0.0001
HIV status	1.303	0.828 - 2.050	0.25

Supplemental table 4: Multivariate analysis of mortality outcome with age, lactate levels, HIV status and sex as covariates

Variable	OR	95% CI	p-value
Age	1.004	0.999-1.009	0.092
Sex	1.131	0.776-1.652	0.52
Lactate	1.100	1.043-1.160	<.001
HIV status	1.222	0.836-2.937	0.57

Supplemental Figure 1

